- Home
- DSL vs LBPH Comparison
DSL vs LBPH Comparison
Compare DSL & LBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- LBPH
- Stock Information
- Founded
- DSL 2013
- LBPH 2020
- Country
- DSL United States
- LBPH United States
- Employees
- DSL N/A
- LBPH N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- LBPH Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- LBPH Health Care
- Exchange
- DSL Nasdaq
- LBPH Nasdaq
- Market Cap
- DSL 1.4B
- LBPH 1.4B
- IPO Year
- DSL N/A
- LBPH 2021
- Fundamental
- Price
- DSL $12.52
- LBPH $59.69
- Analyst Decision
- DSL
- LBPH Buy
- Analyst Count
- DSL 0
- LBPH 8
- Target Price
- DSL N/A
- LBPH $52.29
- AVG Volume (30 Days)
- DSL 412.7K
- LBPH 1.1M
- Earning Date
- DSL 01-01-0001
- LBPH 11-07-2024
- Dividend Yield
- DSL 10.30%
- LBPH N/A
- EPS Growth
- DSL N/A
- LBPH N/A
- EPS
- DSL N/A
- LBPH N/A
- Revenue
- DSL N/A
- LBPH N/A
- Revenue This Year
- DSL N/A
- LBPH N/A
- Revenue Next Year
- DSL N/A
- LBPH N/A
- P/E Ratio
- DSL N/A
- LBPH N/A
- Revenue Growth
- DSL N/A
- LBPH N/A
- 52 Week Low
- DSL $10.22
- LBPH $3.60
- 52 Week High
- DSL $12.96
- LBPH $59.95
- Technical
- Relative Strength Index (RSI)
- DSL 40.76
- LBPH 79.25
- Support Level
- DSL $12.55
- LBPH $59.71
- Resistance Level
- DSL $12.77
- LBPH $59.87
- Average True Range (ATR)
- DSL 0.14
- LBPH 0.23
- MACD
- DSL 0.00
- LBPH -0.92
- Stochastic Oscillator
- DSL 34.13
- LBPH 76.99
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end fund. The fund's primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in securities, including money market funds, foreign corporate bonds, us corporate bonds, bank loans, collateralized loan obligations, and municipal bonds. The portfolio of the fund consists of various industries such as Healthcare, Technology, Construction, Automotive, Insurance, Beverage, Pharmaceuticals, Leisure, and others.
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.